Accepted Manuscript

Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center


Kevin J. Felice D.O., Charles H. Whitaker M.D., Qian Wu M.D., Daniel T. Larose Ph.D., Guo Shen Ph.D., Allan L. Metzger M.D., Randall W. Barton Ph.D.

PII: S0960-8966(18)30186-X DOI: 10.1016/j.nmd.2018.06.005

Reference: NMD 3564

To appear in: Neuromuscular Disorders

Received date: 9 March 2018 Revised date: 16 May 2018 Accepted date: 10 June 2018



Please cite this article as: Kevin J. Felice D.O., Charles H. Whitaker M.D., Qian Wu M.D., Daniel T. Larose Ph.D., Guo Shen Ph.D., Allan L. Metzger M.D., Randall W. Barton Ph.D., Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center, *Neuromuscular Disorders* (2018), doi: 10.1016/j.nmd.2018.06.005

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Highlights

- We report the sensitivity and clinical utility of the anti-cN1A antibody test in sporadic inclusion body myositis (IBM).
- This is a retrospective review of 40 patients with clinico-pathologically defined or clinically defined IBM.
- The anti-cN1A antibody test has limited diagnostic utility in IBM.



Download English Version:

https://daneshyari.com/en/article/8957383

Download Persian Version:

https://daneshyari.com/article/8957383

<u>Daneshyari.com</u>